BAJAJ BROKING
Glenmark Pharmaceuticals’ Board approved an interim dividend of ₹2.50 per equity share (FV ₹1) for FY26, aggregating ~₹705.50 million. Record date: Friday, Oct 3, 2025. The dividend will be paid within 30 days of declaration.
Source: Glenmark Pharmaceuticals Exchange Filing | Sept 26, 2025
Disclaimer: Informational only. Please refer to official filings for complete context.
As quoted in the press release of Glenmark (NSE/BSE Exchange Filings), the company has declared an interim dividend of ₹2.50 per equity share for FY26. The filing specifies a record date of Friday, October 3, 2025, with disbursement within 30 days from the date of declaration. The aggregate outgo is approximately ₹70.55 crore.
Also Read: Supreme Petrochem commissions 70,000 TPA ABS production line in Maharashtra
Dividend: ₹2.50 per share (FV ₹1)
Aggregate outgo: ₹70.55 crore.
Record date: Oct 3, 2025 (Friday)
Payout: Within 30 days of declaration
Also Read: Ceigall India wins Rs. 509 crore GMADA road project bid
The company announced a dividend that reflects steady cash flows. While it may not change overall yield numbers in a big way, it shows a regular payout pattern. This is useful for investors who track income dates.
For long-term shareholders, the prominent factors stay the same like earnings performance, progress in projects, and cost control. The dividend received simply works as a short-term marker in the reporting cycle.
Also Read: DIPAM rejects proposed BHEL-REC joint venture for renewable projects
As of 26 September 2025, 1:27 PM IST, Glenmark share price is trading at ₹1,965.00 per share on the NSE, down by 3.24%.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading